Publications Archives - Page 3 of 3 - Alzheon | Preserving Future Memories

29 Mar, 2017

ALZ-801 Brain Penetration, PK/PD Analyses And Clinical Dose Projection Form The Basis For Confirmatory Phase 3 Study In Alzheimer’s Disease

alzheon2019-09-23T12:10:50-04:00March 29th, 2017|

29 Mar, 2017

Tramiprosate Efficacy in APOE4 Homozygous Subjects with AD: Larger Effects in Mild Patient Subgroups

alzheon2019-09-23T12:10:50-04:00March 29th, 2017|

9 Dec, 2016

Phase 1 Program of ALZ-801, a Novel Prodrug of Tramiprosate with Improved Tolerability, Supports Bridging to Upcoming Phase 3 Program

alzheon2019-09-23T12:10:50-04:00December 9th, 2016|

28 Oct, 2016

Clinical Benefits of Tramiprosate in Alzheimer’s Disease Are Associated with Higher Number of APOE4 Alleles: The “APOE4 Gene-Dose Effect”

alzheon2019-09-23T12:10:50-04:00October 28th, 2016|

24 Jul, 2016

Clinically Meaningful Cognitive and Functional Improvements with Tramiprosate In Alzheimer’s Disease (AD) Patients with APOE4/4 Genotype: Subgroup Analyses from Two Phase 3 Studies

alzheon2019-09-23T12:10:52-04:00July 24th, 2016|

24 Jul, 2016

Phase 1 Development Of ALZ-801, a Novel Beta Amyloid Anti-aggregation Prodrug of Tramiprosate With Improved Drug Properties, Supporting Bridging to the Phase 3 Program

alzheon2019-09-23T12:10:53-04:00July 24th, 2016|

11 Mar, 2016

Efficacy of tramiprosate in APOE4 heterozygous patients with mild to moderate AD: combined sub-group analyses from two Phase 3 trials

alzheon2019-09-23T12:10:53-04:00March 11th, 2016|

11 Mar, 2016

Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous AD patients: efficacy and safety analyses from two Phase 3 trials

alzheon2019-09-23T12:10:53-04:00March 11th, 2016|

27 Oct, 2015

Cognitive and Functional Efficacy of Tramiprosate in APOE4+ Patients with Mild to Moderate Alzheimer’s Disease: Subgroup Analyses of the Phase 3 North American and European Trials

alzheon2019-09-23T12:10:53-04:00October 27th, 2015|

20 Mar, 2015

Analyses of tramiprosate Phase 3 trials show improvement in cognition and function in APOE4 positive alzheimer’s disease subjects reaching 4 point improvement from placebo on ADAS-cog in homozygous APOE4 subjects, and support development of ALZ-801, a novel prodrug of tramiprosate with optimized drug properties

alzheon2019-09-23T12:10:54-04:00March 20th, 2015|